Colossal Biosciences Eyes $30 Billion: Is the De-extinction Bet Paying Off?

When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils, we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation.

Now, roughly 16 months later, the startup is in talks to raise new funding at a $20 billion to $30 billion valuation, Axios reported.

Key Takeaways

• Exponential Valuation Growth: Colossal Biosciences, initially valued at $10.2 billion, is now reportedly seeking new funding at a staggering $20-30 billion, showcasing rapid investor confidence in its diversified deep-tech portfolio.
• Strategic Diversification Drives Revenue: Beyond its headline-grabbing de-extinction projects, Colossal has successfully spun out and developed high-value ventures in computational biology (Form Bio), AI-driven predictive modeling (Astromech), and environmental solutions (Breaking), generating significant revenue streams and proving the broad applicability of its core scientific platforms.
• Pioneering Dual-Use Technology: The company’s advanced genetic engineering and reproductive technologies, initially developed for species resurrection, are finding practical applications in existing conservation efforts, human fertility, and even offer future potential in emerging markets like biodiversity credits.

From Dire Wolves to Deep Tech: Colossal Biosciences Eyes a Staggering $30 Billion Valuation on the Back of Diversified Innovation

The world of biotechnology is no stranger to ambitious undertakings, but few companies capture the public imagination quite like Colossal Biosciences. The five-year-old startup first made waves with its audacious mission to “de-extinct” species like the woolly mammoth and the dire wolf. Last year, when news broke of its $10.2 billion valuation, we posited that the company’s true value lay not just in its controversial resurrection efforts, but in the groundbreaking technologies it was developing along the way.

Fast forward approximately 16 months, and Colossal Biosciences is once again commanding headlines, this time for its staggering financial ascent. According to a recent Axios report, the company is now in discussions to raise fresh capital, potentially at an eye-watering valuation of $20 billion to $30 billion. While the specific investors leading this new round and the exact capital sought remain undisclosed, the implied growth from its previous valuation is nothing short of meteoric. Crucially, this valuation leap is underpinned by a significant development: Colossal has begun generating revenue over the last year, a testament to its strategic diversification beyond its initial, high-profile de-extinction projects.

The Valuation Leap: A Vote of Confidence in Deep Tech

The potential for a near-tripling in valuation in such a relatively short period speaks volumes about the investor community’s belief in Colossal’s long-term vision and the commercial viability of its scientific platforms. This isn’t merely speculative hype; it’s a recognition of the tangible progress made in transforming ambitious scientific research into marketable solutions. Colossal co-founder and CEO Ben Lamm had previously outlined three key revenue streams for the business, and the company appears to be executing on that multi-pronged strategy with remarkable efficiency.

Beyond De-Extinction: A Portfolio of Pioneering Tech

At its core, Colossal Biosciences is a synthetic biology company, leveraging advanced gene-editing tools, reproductive technologies, and computational biology platforms. While the de-extinction narrative often dominates, the true financial engine of the company is its ability to find broad applications for these foundational technologies across various sectors.

Strategic Spinoffs & Their Impact

A significant component of Colossal’s revenue and valuation growth stems from its successful strategy of spinning out specialized companies that harness its core science for distinct commercial purposes. This approach allows Colossal to maintain focus on its primary de-extinction goals while simultaneously commercializing its underlying technological advancements in adjacent markets.

• Form Bio: This computational biology platform has already secured a substantial $30 million in funding. Form Bio provides critical tools and infrastructure for managing, analyzing, and interpreting vast biological datasets, a bottleneck for innovation across pharmaceuticals, agriculture, and broader life sciences research. Its independent valuation and funding underscore the market demand for sophisticated bioinformatics solutions derived from Colossal’s internal development.
• Astromech: Valued at an impressive $2 billion in March, Astromech is an AI-driven predictive modeling company squarely focused on biology and life sciences. By applying advanced artificial intelligence to biological systems, Astromech aims to accelerate discovery, optimize processes, and predict outcomes in areas ranging from drug development to ecosystem modeling. Its rapid ascent signals the immense value placed on AI’s transformative potential in understanding and manipulating complex biological processes.
• Breaking: This startup tackles one of the planet’s most pressing environmental challenges: plastic pollution. By leveraging Colossal’s expertise in synthetic biology, Breaking aims to develop enzymatic or microbial solutions to effectively degrade plastics, offering a novel approach to waste management and circular economy initiatives. While its valuation isn’t publicly disclosed in the same way as Form Bio or Astromech, its mission aligns with a massive global market need for sustainable solutions.

Conservation-as-a-Service & Government Partnerships

Colossal’s advanced conservation technology has not gone unnoticed by governmental bodies. The company has secured contracts with both the U.S. government and the United Arab Emirates, with the UAE recently investing $60 million in the company, as reported by Wired. These partnerships highlight the practical, immediate applications of Colossal’s genetic and reproductive technologies for existing wildlife conservation efforts, such as genetic rescue, disease resistance, and habitat restoration, offering a robust revenue stream that complements its more futuristic endeavors.

Expanding Horizons: New Species & Human Applications

The company’s Dallas headquarters, a sprawling 55,000-square-foot facility, is a hub of continuous innovation. Colossal keeps finding new applications for its core science, expanding its reach into diverse biological challenges. In late April, it added the bluebuck antelope as its sixth target species for de-extinction, demonstrating its ongoing commitment to its foundational mission. Furthermore, its nonprofit conservation arm, the Colossal Foundation, forged a partnership with the University of Tasmania to combat a contagious facial cancer threatening Tasmanian devils, showcasing its immediate impact on current conservation crises.

Perhaps one of the most intriguing future spin-offs is the company’s artificial animal womb technology. Ben Lamm told TechCrunch last year that this technology has significant potential applications for human fertility treatment, and in May, he indicated to Rolling Stone that it could be ready as early as next year. This potential foray into human reproductive health represents a massive market opportunity and further underscores the dual-use nature of Colossal’s pioneering research.

Future Revenue Streams: Biodiversity Credits

Looking further down the line, Lamm envisions a novel revenue stream: biodiversity credits. Should Colossal succeed in reintroducing extinct animals like the woolly mammoth and the dodo bird into their native habitats, these revitalized ecosystems could generate biodiversity credits, analogous to carbon credits. This market-based mechanism would allow companies or governments to invest in biodiversity restoration, providing a sustainable financial model for large-scale ecological engineering projects.

The De-Extinction Mandate: Ambition Meets Controversy

While the financial narrative is compelling, it’s impossible to discuss Colossal Biosciences without addressing its audacious de-extinction mandate. The idea of bringing back the woolly mammoth, the dodo, and the dire wolf from the annals of extinction continues to spark intense ethical debates and scientific scrutiny. Critics often question the ecological wisdom, the potential unforeseen consequences, and the sheer feasibility of such projects. However, it is precisely this “moonshot” ambition that drives the development of the cutting-edge technologies that are now finding numerous commercial applications. The controversy, while ever-present, often serves to highlight the foundational scientific breakthroughs that have broader, less contentious, and immediately valuable uses.

Riding the Deep-Tech Wave

Colossal Biosciences’ valuation surge is not an isolated phenomenon but rather emblematic of a broader investment boom in deep-tech sectors. Investors are pouring unprecedented capital into areas like longevity tech, alternative energy, quantum computing, and advanced biotechnology. These sectors share common characteristics: they aim to solve grand challenges, require substantial R&D, have long development cycles, and promise transformative, long-term impact. Colossal, with its fusion of synthetic biology, AI, and environmental aims, sits squarely within this high-growth, high-impact investment landscape, making it a darling for venture capitalists looking for the next paradigm shift.

Colossal did not respond to our request for comment regarding the new funding round.

Bottom Line

Colossal Biosciences has rapidly evolved from a visionary de-extinction startup into a diversified deep-tech powerhouse. Its reported pursuit of a $20-30 billion valuation underscores a profound shift in how investors perceive the company – not just as a bold scientific experiment, but as a generator of commercially viable, cutting-edge biotechnologies. While the ethical and ecological debates around species resurrection will undoubtedly persist, Colossal’s strategic spin-offs, government partnerships, and expanding application pipeline in areas from human fertility to environmental remediation prove that its true, multi-billion-dollar value lies in its foundational genetic engineering and computational biology platforms, making it a critical player in the ongoing deep-tech revolution.